{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-019738","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.684599+00:00","generated_at":"2026-06-20T04:47:12.808282+00:00","sec_items":["2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inovio cuts 11% of workforce, expects $4.3M annual savings; securities class action settled for $44M","bullets":["Reduced headcount by 24 employees (11% of full-time staff); one-time charge of $1.1M in Q1 2023.","Expected annual savings of ~$4.3M from reorganization and prior program discontinuations.","Court granted final approval of $44M securities class action settlement: $30M cash (paid by insurers) plus $14M in stock (initially 7M shares; <5% of outstanding).","Key data readouts expected Q1 2023 for INO-3107 (RRP) and VGX-3100 (cervical HSIL) trials.","Restructuring redirects resources to lead DNA medicine candidates; 2022 Q4 results planned for March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-019738","json":"https://secwatch.observer/filing/0001193125-23-019738.json","markdown":"https://secwatch.observer/filing/0001193125-23-019738.md","text":"https://secwatch.observer/filing/0001193125-23-019738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/0001193125-23-019738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/d295438d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T04:47:12.808282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cec88d8bfa841d20b746a437753baf0a53f265a2","claim":"INOVIO PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $1.1 million (approximately 24 employees).","evidence_excerpt":"On January 31, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) committed to and communicated a corporate reorganization plan, including a reduction in force (the “ Reduction ”). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company has reduced its overall headcount by approximately 24 employees, which represents 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. The Company expects to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/0001193125-23-019738-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.1 million"},{"label":"Headcount","value":"approximately 24 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}